Medtronic, Inc. (Medtronic) will consolidate its businesses into two operating groups, each designed to leverage technologies and customers, effective August 31, 2009. One group will combine the company’s Cardiac Rhythm Disease Management (CRDM), CardioVascular and Physio-Control businesses and the other group will combine its Spinal and Biologics, Neuromodulation, Diabetes, and Surgical Technologies businesses.
To support this new organizational structure the leadership changes are as follows:
Spinal and Biologics, Neuromodulation, Diabetes, and Surgical Technologies Group
Chris O’Connell has been promoted to the new position of executive vice president and group president for this newly created group. O’Connell was formerly president of the company’s Diabetes business. Reporting to O’Connell will be Bob Blankemeyer, senior vice president and president, Surgical Technologies; Steve La Neve, senior vice president and president, Spinal and Biologics; Katie Szyman, who has been named as senior vice president and president, Diabetes, and formerly served as senior vice president of Strategy and Innovation; and Tom Tefft, who has been named senior vice president and president, Neuromodulation, and formerly served as vice president and corporate controller.
CRDM, CardioVascular and Physio-Control Group
The company is currently conducting an external search for a new executive vice president and group president. Reporting to this leader will be Pat Mackin, senior vice president and president, CRDM; Scott Ward, senior vice president and president, CardioVascular; and Brian Webster, president, Physio-Control.
International Operations
Jean-Luc Butel has been promoted to the new position of executive vice president and group president, International. Butel was formerly senior vice president and president, International.
Advancing Clinical and Economic Evidence
Dr. Rick Kuntz has been named senior vice president and chief scientific, clinical and regulatory officer. Dr. Kuntz was formerly senior vice president and president, Neuromodulation.
“I am confident that these organizational and leadership changes will further strengthen our ability to fulfill Medtronic’s Mission, fuel innovation and position us to continue to deliver market leading financial performance,” said Hawkins.